Skip to main content

Genetic analysis of the ATP11B gene in Chinese Han population with cerebral small vessel disease



A loss-of-function mutation in ATPase phospholipid transporting 11-B (putative) (ATP11B) gene causing cerebral small vessel disease (SVD) in vivo, and a single intronic nucleotide polymorphism in ATP11B: rs148771930 that was associated with white matter hyperintensities burden in European patients with SVD, was recently identified. Our results suggest that ATP11B may not play an essential role in SVD in the Chinese population.


We performed target region sequencing including ATP11B gene in 182 patients with sporadic SVD, and identified five rare variants and two novel variants of ATP11B. A case–control study was then performed in 524 patients and matched 550 controls to investigate the relationship between ATP11B and sporadic SVD in the Chinese Han population. Although none of these variants were significantly associated with SVD in our samples, it is important to mention that we identified a novel variant, p. G238W, which was predicted to be pathogenic in silico. This variant was present in our cohort of patients with an extremely low frequency and was absent in the controls.


Our results suggest that ATP11B may not play an essential role in SVD in the Chinese population.


Cerebral small vessel disease (SVD) is a syndrome characterized by clinical, neuroimaging, and neuropathological manifestations caused by disorders that affect small cerebral vessels, including arteries, arterioles, capillaries, and venules in the brain [1]. It contributes to approximately 20% of stroke cases and 45% of vascular dementia worldwide [2, 3]. White matter hyperintensities (WMH) is an important neuroimaging marker for diagnosing SVD because of its mild clinical symptoms, especially in the early stages of the disease [1]. Meanwhile, WMH is considered to be mainly caused by breakdown of the blood–brain barrier (BBB), loss of oligodendrocytes, and demyelination [4]. Although there is no exact molecular mechanism of pathogenesis, increasing evidence shows that BBB leakage is associated with SVD [5,6,7]. Endothelial cells (ECs) are an essential constituent of the BBB, and endothelial dysfunction is assumed to be a critical contributor to SVD [8, 9].

Recently, Rikesh et al. identified a mutation that leads to a truncated protein in the ATPase phospholipid transporting 11-B (putative) (ATP11B) gene causing EC dysfunction in a rat model of SVD. They also found an intronic single nucleotide polymorphism (SNP) in ATP11B: rs148771930, which was associated with WMH burden in European patients with SVD. These results suggest that loss-of-function mutations in ATP11B may result in the WMH of SVD, and rare variants in the ATP11B cloud are risk factors for SVD in European population [10]. However, there is no genetic evidence for ATP11B mutations in the Chinese population.

Here, we performed a comprehensive ATP11B variant screening in sporadic SVD patients and healthy controls to further investigate the relationship between ATP11B and sporadic SVD in the Chinese Han population.


This study enrolled 1074 Chinese Han subjects including 524 patients with SVD and 550 healthy controls. There was no significant statistical difference in age (p = 0.290), sex (p = 0.125) and hypertension (p = 0.108) between SVD patients and control subjects (Supplemental Table 1).

A total of 48 genetic variants were identified after NGS in 182 SVD patients (Supplemental Table 2), and we eventually determined seven variants with potential contribution to disease after variant filtration sanger sequencing validation (Fig. 1).

Fig. 1
figure 1

The process of variant filtration

All seven variants identified in ATP11B were heterozygous except p.E1103K. One of the three loci of p.E1103k was homozygous in one patient, and the others were heterozygous carried by two patients. None of these variants appeared to have significantly different allele frequencies between patients and controls (Tables 1 and 2). The altered amino acid influenced by p.G238W is evolutionarily conserved from human to fish (Fig. 2).

Table 1 Variants found in ATP11B in SVD patients and healthy controls
Table 2 Geographical and ethnic differences in minor allele frequency of ATP11B variants & protein function prediction of coding variants
Fig. 2
figure 2

Evolutionary conservation analysis of altered amino acid. red: this amino acid residue is evolutionarily conserve


The ATP11B gene encodes probable phospholipid-transporting ATPase IF protein (NM_014616.3). ATP11B is a catalytic component of the P4-ATPase flippase complex that catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes [11,12,13]. Rikesh et al. hypothesized that loss of ATP11B may cause endothelial dysfunction because of blocked vesicular transport from the trans-Golgi network to the plasma membrane. They showed that HSP90α, which is secreted from dysfunctional ECs, is an important factor in interrupting the maturation of oligodendrocytes, and eventually contributes to impaired myelination. Therefore, ATP11B may be closely associated with the WMH of SVD [10].

In our study, we failed to identify the SNP: rs148771930, which was previously reported to be associated with WMH burden in European patients with SVD; this might be due to the fact that different ethnic groups have different genetic backgrounds (Table 2). However, we identified five rare variants and two novel variants by NGS of ATP11B in Chinese Han patients with sporadic SVD and healthy controls. Among them, p.G238W, p.P441L (rs186142123), c.1763-5 T > -, and c.3319-4G > T (rs773539019) were carried by the patients only. None of these variants were significantly associated with SVD in the Chinese samples. Given that the sample size was too small to capture these low-frequency variants, larger samples are needed to clarify a more comprehensive distribution of ATP11B in various populations and areas.

It is worth mentioning that we identified a novel variant, p.G238W. It is located in exon 9 of ATP11B, a region encoding a part of probable phospholipid-transporting ATPase IF, and p. G238W seems to have pathogenic prediction in silico based on three different bioinformatics analyses (Table 2). In addition, the altered amino acid influenced by p.G238W is evolutionarily conserved across multiple species (Fig. 2). This evidence, together with the extremely low minor allele frequency of this rare variant in our study (Table 2), suggest that the potential effect on the biologic al function of ATP11B merits further investigation.


In conclusion, our study failed to reproduce the association between the polymorphism of ATP11B and SVD in the Chinese Han population. Further studies in various populations are needed to investigate the role of ATP11B in the pathogenesis of SVD.



This study recruited 524 Chinese Han sporadic SVD patients from the Neurology Department of the First Affiliated Hospital of Zhengzhou University between March 2018 and October 2021. Diagnosis was performed by both neurologists and neuroimaging [14], and the severity of WMH was quantified on fluid-attenuated inversion recovery (FLAIR) and T2-weighted magnetic resonance imaging scans (MRI). The following inclusion and exclusion criteria were used:

The inclusion criteria were as follows: (1) age > 18 years; (2) the Fazekas score of WMH is from 2 to 3 on T2-FLAIR brain MRI scans [15]; (3) cognitive dysfunction & memory impairment caused by vascular dementia; (4) psychiatric disorder influenced by cerebrovascular disease.

Exclusion criteria: (1) a cerebral infarct larger than one third the volume of the cerebellar hemisphere identified on diffusion-weighted imaging; (2) dementia due to confirmed neurodegenerative diseases; (3) an aneurysm (diameter > 3 mm), or a history of cerebral vascular malformation or aneurysmal subarachnoid hemorrhage; (4) mental diseases diagnosed according to the diagnostic and statistical manual of mental disorders-5; (5) intracranial infection, traumatic brain injury, brain tumors, and epilepsy; (6) a family history of cerebrovascular disease or vascular dementia, or harboring mutations in NOTCH3, HTRA1, and COLA1/2 genes [16].

In addition, 550 ethnicity-, age-, and sex-matched healthy individuals were enrolled as controls. They were confirmed to be healthy by on history of neurological and psychiatric diseases, normal neuroimaging and laboratory examination. In addition, hypertension and advanced age are well-known risk factors for SVD [17, 18]; therefore, we performed Student’s t-tests and Chi-square tests to assess the differences in these potential confounders between patients and controls.

Next generation sequencing (NGS) and bioinformatics analysis

In our previous work, we performed target region sequencing including the ATP11B gene in 182 patients with sporadic SVD [19]. Genomic DNA was extracted from the peripheral blood collected from patients and controls using a genomic DNA extraction kit (#DP1101, BioTeke, Beijing) based on standard protocols. NGS of whole exons and adjacent intron regions of ATP11B (Supplemental Table 3) was carried out on an Illumina MiSeq high-throughput sequencing platform (Illumina, San Diego, CA, USA) provided by Phylotree (Zhengzhou) Biotechnology Co., Ltd.

The raw sequencing data was converted into a collection of small fragment sequences called Reads, in the file format Fastaq. Sequencing reads were aligned to human reference genome 19 using the Burrows-Wheeler Aligner (BWA) [20]. Single-nucleotide variant (SNV) calling was performed using both Genome Analysis Toolkit (GATK) [21] and Varscan programs [22], and the called SNV data were then combined. The Annovar program was used for SNV annotation [23]. The functional effect of non-synonymous variants was assessed by the PolyPhen-2, SIFT, and Mutation Taster [24,25,26]. The evolutionary conservation analysis of altered amino acids was performed by aligning the sequences of ATP11B across multiple species.

Variant filtration and validation by sanger sequencing

Variant filtration was performed after bioinformatics analysis of raw sequencing data from NGS. First, variants in intron areas (except for splice-site variants), 3 ' UTR and 5 ' UTR areas, and synonymous variants were ruled out. We then queried the Genome Aggregation Database (gnomAD) ( and filtered out variants whose minor allele frequency (MAF) was greater than 0.1% based on gnomAD. Finally, sanger sequencing was performed to confirm the remaining variants. Specific primers for exons 9, 13, 17, 25, 27, 28 and 29 of ATP11B were designed using Primer 6 software (Supplemental Table4). These exons and corresponding exon–intron boundaries were amplified using the polymerase chain reaction (PCR). DNASTAR Lasergene MegAlign (v7.1.0) and Chromas (v2.33) were used to conduct sequence alignment. All variants not validated by sanger sequencing were exclude (Fig. 1).

SNP genotyping

SNaPshot analysis of SNP genotypes was performed to confirm the remaining variants after variant filtration in the samples of patients and controls, using a SNaPshot Multiplex kit system (Applied Biosystems, Foster City, CA, USA). Specific primers were designed using the Primer 3 Software (Supplemental Table 5). SNaPshot results were analyzed using Gene Mapper v4.1 software (Foster City, CA, USA).

Statistical analysis

Pearson’s \({x}^{2}\) test was used to compare allele frequencies between patients and controls. The Student’s t-test was used to assess the difference in age between patients with SVD and health controls (age at SVD onset for patients vs. age at recruitment for healthy controls). The chi-square test was used to assess the difference in sex and history of hypertension between the two groups. The p value, OR, and 95% confidence intervals were calculated using SPSS (v.21.0), and statistical significance was set at p < 0.05.

Availability of data and materials

All data generated or analysed during this study are included in this article and it’s supplementary material. The target capture sequencing data including ATP11B can be freely and openly accessed at the Sequence Read Archive of the National Center for Biotechnology Information (NCBI) ( database with the ID SUB11084355. These data have been processed and will be released on January 1, 2023. ATP11B gene sequences of multiple species were obtained from Uniport (



ATPase phospholipid transporting 11-B


Small vessel disease


White matter hyperintensities


Blood-brain barrier


Endothelial cells


Single nucleotide polymorphism


Fluid-attenuated inversion recovery


Magnetic resonance imaging scans


Next Generation Sequencing


Burrows-Wheeler Aligner


Single-nucleotide variant


Genome Analysis Toolkit


Polymerase chain reaction


Genome Aggregation Database


Minor allele frequency


  1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701.

    Article  Google Scholar 

  2. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672–713.

    Article  Google Scholar 

  3. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;28(3):491–9.

    Article  CAS  Google Scholar 

  4. De Silva TM, Miller AA. Cerebral Small Vessel Disease: Targeting Oxidative Stress as a Novel Therapeutic Strategy? Front Pharmacol. 2016;7:61.

    Article  Google Scholar 

  5. Topakian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leucoaraiosis. J Neurol Neurosurg Psychiatry. 2010;81(2):192–7.

    Article  CAS  Google Scholar 

  6. Huisa BN, Caprihan A, Thompson J, Prestopnik J, Qualls CR, Rosenberg GA. Long-Term Blood-Brain Barrier Permeability Changes in Binswanger Disease. Stroke. 2015;46(9):2413–8.

    Article  CAS  Google Scholar 

  7. Zhang CE, Wong SM, van de Haar HJ, Staals J, Jansen JF, Jeukens CR, Hofman PA, van Oostenbrugge RJ, Backes WH. Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease. Neurology. 2017;88(5):426–32.

    Article  CAS  Google Scholar 

  8. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38(6):323–37.

    Article  CAS  Google Scholar 

  9. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease–systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.

    Article  CAS  Google Scholar 

  10. Rajani RM, Quick S, Ruigrok SR, Graham D, Harris SE, Verhaaren BFJ, et al. Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats. Sci Transl Med. 2018;10(448):eaam9507.

  11. Tang X, Halleck MS, Schlegel RA, Williamson P. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science. 1996;272(5267):1495–7.

    Article  CAS  Google Scholar 

  12. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, et al. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest. 2013;123(5):2119–30.

    Article  CAS  Google Scholar 

  13. Wang J, Li W, Zhou F, Feng R, Wang F, Zhang S, Li J, Li Q, Wang Y, Xie J, et al. ATP11B deficiency leads to impairment of hippocampal synaptic plasticity. J Mol Cell Biol. 2019;11(8):688–702.

    Article  CAS  Google Scholar 

  14. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.

    Article  Google Scholar 

  15. Fazekas F, Kleinert R, Offenbacher H, Payer F, Schmidt R, Kleinert G, Radner H, Lechner H. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. AJNR Am J Neuroradiol. 1991;12(5):915–21.

    CAS  Google Scholar 

  16. Tan RYY, Traylor M, Megy K, Duarte D, Deevi SVV, Shamardina O, Mapeta RP, Ouwehand WH, Gräf S, Downes K, et al. How common are single gene mutations as a cause for lacunar stroke? A targeted gene panel study. Neurology. 2019;93(22):e2007–20.

    Article  CAS  Google Scholar 

  17. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke. 2008;39(10):2712–9.

    Article  Google Scholar 

  18. Ryu WS, Woo SH, Schellingerhout D, Chung MK, Kim CK, Jang MU, Park KJ, Hong KS, Jeong SW, Na JY, et al. Grading and interpretation of white matter hyperintensities using statistical maps. Stroke. 2014;45(12):3567–75.

    Article  Google Scholar 

  19. Wang Y, Shi C, Li Y, Yu W, Wei S, Fan Y, Mao C, Yang Z, Yu L, Zhao Z, et al. Genetic Study of Cerebral Small Vessel Disease in Chinese Han Population. Front Neurol. 2022;13:829438.

    Article  Google Scholar 

  20. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics. 2010;26(5):589–95.

    Article  Google Scholar 

  21. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.

    Article  CAS  Google Scholar 

  22. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568–76.

    Article  CAS  Google Scholar 

  23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.

    Article  Google Scholar 

  24. Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812–4.

    Article  CAS  Google Scholar 

  25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248–9.

    Article  CAS  Google Scholar 

  26. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods. 2010;7(8):575–6.

    Article  CAS  Google Scholar 

Download references


We want to thank the patients and normal controls for their participation in this study.


This work was supported by National Natural Science Foundation of China [82171300] and Medical Science and Technology Research Project of Henan Province [SBGJ202101016] to Dr Yu-sheng Li, and the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2020-PT310-01]. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Authors and Affiliations



Y. L. and Y. X. contributed to the conception and design of the study. W. Y. performed the experiment and wrote the manuscript. W. Y., Y. W. contributed significantly to data analysis and revision of manuscript. Y. G., C. S., and Y. F. contributed to data analysis. L. Y., Z. Z. and S. L. contributed to data acquisition and analysis.

Corresponding authors

Correspondence to Yu-Ming Xu or Yu-Sheng Li.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of First Affiliated Hospital of Zhengzhou University and informed consent was obtained from all the participating subjects (2020-KY-0334–001).

Consent for publication

Not applicable

Competing interests

All authors report no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, WK., Wang, YC., Gao, Y. et al. Genetic analysis of the ATP11B gene in Chinese Han population with cerebral small vessel disease. BMC Genomics 23, 822 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Cerebral small vessel disease
  • ATP11B gene
  • Variant
  • Chinese Han population